Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus
Elsa Martins, Vishala L Chindalore, X Rebecca Sheng, Aaron V Schroeder, Vivian Chen, Hardik Mody, Audrey Arjomandi, Huiyan (Ashley) Mao, Imran Hassan, Iwona Dankiewicz-Fares, Svetlana Agachi, Theodore A Omachi, Jay P Garg, William F Pendergraft · 2026
Read Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus by Elsa Martins, Vishala L Chindalore, X Rebecca Sheng, Aaron V Schroeder, Vivian Chen, Hardik Mody, Audrey Arjomandi, Huiyan (Ashley) Mao, Imran Hassan, Iwona Dankiewicz-Fares, Svetlana Agachi, Theodore A Omachi, Jay P Garg, William F Pendergraft (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289224.txt.
Description
Elsa Martins and a large team report a 2026 phase Ib trial of mosunetuzumab given under the skin in systemic lupus erythematosus. Mosunetuzumab is a lab-made antibody that links T cells to B cells so T cells can remove B cells. The open-label study tested safety, drug levels in blood, and effects on immune cells across several centers.
Fifteen adults with active, antibody-positive lupus joined between January 2022 and December 2023. Some got one fixed dose, while others got a small first dose then a larger dose on day 8, up to 60 mg in the highest group. Two people stopped care because of side effects during treatment. No severe cytokine release events or nerve toxicity linked to immune cells were reported, which supports further careful study.
Catalog record
| CREATOR | Elsa Martins, Vishala L Chindalore, X Rebecca Sheng, Aaron V Schroeder, Vivian Chen, Hardik Mody, Audrey Arjomandi, Huiyan (Ashley) Mao, Imran Hassan, Iwona Dankiewicz-Fares, Svetlana Agachi, Theodore A Omachi, Jay P Garg, William F Pendergraft |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37380 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |